Ronald J. Falk

Ronald J. Falk's AcademicInfluence.com Rankings

Ronald J. Falk

Philosophy

#4800

World Rank

#7449

Historical Rank

Logic

#2185

World Rank

#3120

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ronald J. Falk's Degrees

Doctorate Medicine University of Pennsylvania

Why Is Ronald J. Falk Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronald J. Falk's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. (2013) (4083)
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. (1994) (3126)
Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. (1988) (1360)
Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. (1990) (1228)
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. (2002) (1106)
Small-vessel vasculitis. (1997) (848)
International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) (1999) (571)
Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis (2005) (440)
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. (2007) (411)
Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. (1990) (381)
Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. (1996) (375)
Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3 (2004) (370)
Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease (2014) (357)
Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. (1997) (333)
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. (2003) (332)
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. (2012) (329)
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. (2005) (318)
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. (1996) (315)
Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. (1989) (300)
Nomenclature of Cutaneous Vasculitis (2018) (296)
Antineutrophil cytoplasmic autoantibodies and associated diseases: a review. (1990) (295)
Efficacy of treatment for unexplained infertility. (1998) (293)
Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. (1992) (274)
Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. (1994) (268)
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. (2008) (250)
Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. (1992) (249)
C5a receptor (CD88) blockade protects against MPO-ANCA GN. (2014) (244)
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. (2005) (239)
Interleukin-8 delays spontaneous and tumor necrosis factor-alpha-mediated apoptosis of human neutrophils. (1998) (237)
Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. (2006) (236)
Antibodies Against Granule Proteins Activate Neutrophils In Vitro (1991) (232)
Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. (2000) (228)
Mycophenolate mofetil therapy in lupus nephritis: clinical observations. (1999) (225)
Polyantigenic Expansion of Basement Membrane Constituents in Diabetic Nephropathy (1983) (225)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (222)
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. (2013) (214)
ANCA small-vessel vasculitis. (1997) (207)
Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. (2005) (205)
Clinical and pathologic features of fibrillary glomerulonephritis. (1992) (204)
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. (2013) (204)
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. (2000) (198)
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. (1983) (198)
Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. (1996) (197)
Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. (1997) (192)
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. (2006) (191)
Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. (1990) (186)
Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. (1985) (185)
Cutaneous and Systemic Manifestations of Drug-Induced Vasculitis (2002) (182)
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. (2010) (181)
A review of therapeutic studies of idiopathic membranous glomerulopathy. (1995) (178)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (163)
Venous thromboembolism in patients with membranous nephropathy. (2012) (161)
Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. (2001) (160)
Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. (1999) (157)
Increased red-cell sodium-lithium countertransport in normotensive sons of hypertensive parents. (1982) (156)
SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. (2007) (156)
Molecular Cloning, Genomic Structure, and Expression Analysis of MUC20, a Novel Mucin Protein, Up-regulated in Injured Kidney* (2004) (151)
Periodontal disease adversely affects the survival of patients with end-stage renal disease. (2009) (143)
The pathology of vasculitis involving the kidney. (1994) (136)
Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. (2001) (128)
The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. (1995) (126)
Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. (2005) (126)
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. (2012) (123)
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. (2013) (121)
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. (2005) (121)
Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. (2000) (117)
ANCA disease: where is this field heading? (2010) (116)
Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. (2014) (115)
The clinical course of ANCA small-vessel vasculitis on chronic dialysis. (2009) (114)
Adult minimal change glomerulopathy with acute renal failure. (1990) (113)
Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis (2011) (113)
Microscopic polyangiitis (microscopic polyarteritis). (2001) (112)
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis (2017) (112)
Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. (2006) (110)
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. (2007) (110)
Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. (2012) (109)
Dermatological Addendum to the 2012 International Chapel Hill Consensus Conference Nomenclature of Vasculitides (2017) (104)
Interstital lung disease in ANCA vasculitis. (2017) (100)
ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. (2000) (99)
Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. (1985) (97)
Diagnostic predictive value of ANCA serology. (1998) (97)
Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. (1994) (96)
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. (2011) (96)
Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015. (2017) (94)
Trends in Long‐Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease (2016) (93)
ANCA are pathogenic--oh yes they are! (2002) (92)
The pathogenic role of antineutrophil cytoplasmic autoantibodies. (1991) (91)
Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways. (2002) (89)
Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. (1998) (89)
Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. (2013) (89)
Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. (1987) (87)
Rituximab therapy for membranous nephropathy: a systematic review. (2009) (87)
The life readiness program: a physical rehabilitation program for patients on hemodialysis. (2000) (87)
Effect of the antiprogestin RU486 on progesterone production by cultured human granulosa cells: inhibition of the ovarian 3B-hydroxysteroid dehydrogenase. (1986) (86)
Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. (2008) (86)
Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. (2004) (84)
Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. (1992) (81)
Severe periodontitis is associated with low serum albumin among patients on maintenance hemodialysis therapy. (2007) (80)
Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. (2000) (79)
High prevalence of sickle cell trait in African Americans with ESRD. (2010) (78)
New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies (2008) (78)
Vasculitis affecting the skin. A review. (1994) (76)
Overview of the Pathogenesis of ANCA-Associated Vasculitis (2015) (76)
Nosology of primary vasculitis (2007) (75)
Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. (1989) (74)
Anti‐myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase (1992) (73)
Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. (2014) (73)
Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. (2004) (73)
ANCA-associated renal disease. (1990) (73)
Monoclonal antibodies to human renal basement membranes: heterogenic and ontogenic changes. (1983) (72)
Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis. (1997) (72)
Clinical and pathological classification of ANCA‐associated vasculitis: what are the controversies? (1995) (71)
Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. (2007) (69)
Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. (2015) (68)
Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes (1992) (65)
Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). (2002) (65)
Ultrastructural localization of the membrane attack complex of complement in human renal tissues. (1987) (63)
Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense (1986) (63)
Target antigens for anti‐neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils (2000) (62)
Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. (1998) (62)
Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. (1994) (60)
Uptake of tritiated progesterone by the uterus of the ovariectomized guinea pig. (1970) (60)
Successful treatment of diffuse alveolar hemorrhage with activated factor VII. (2004) (60)
Diagnostic classification of antineutrophil cytoplasmic autoantibody-associated vasculitides. (1991) (59)
Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase (1994) (59)
Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. (2007) (59)
Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. (2011) (58)
Infections associated with subclavian Uldall catheters. (1983) (58)
ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. (2000) (57)
Synthesis of Complement Components C5, C6, C7, C8 and C9 in Vitro by Human Monocytes and Assembly of the Terminal Complement Complex (1986) (57)
Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease (2004) (56)
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019) (56)
Pathogenesis of vasculitis. (1994) (56)
NPHS2 variation in focal and segmental glomerulosclerosis (2008) (55)
Serum IgA-Fibronectin Aggregates in Patients With IgA Nephropathy and Henoch-Schiinlein Purpura: Diagnostic Value and Pathogenic Implications (1991) (55)
Deposition of the membrane attack complex of complement in bullous pemphigoid. (1984) (54)
Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis (2011) (54)
The role of pathology in the diagnosis of systemic vasculitis. (2007) (54)
Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. (2007) (53)
Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. (1999) (53)
Reduced CD5+CD24hiCD38hi and interleukin‐10+ regulatory B cells in active anti‐neutrophil cytoplasmic autoantibody‐associated vasculitis permit increased circulating autoantibodies (2015) (53)
In vitro studies of progesterone binding proteins in guinea pig uterus. (1972) (51)
Patients with primary membranous nephropathy are at high risk of cardiovascular events. (2016) (50)
Vitronectin: effects on keratinocyte motility and inhibition of collagen-induced motility. (1991) (49)
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. (2007) (49)
Infections Associated With Subclavian Uldall Catheters (1983) (49)
Microarray Studies of Gene Expression in Circulating Leukocytes in Kidney Diseases (2002) (48)
ANCA patients have T cells responsive to complementary PR-3 antigen. (2008) (48)
Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: "step-up" versus "step-down" dose regimens. (1987) (48)
Fostering innovation, advancing patient safety: the kidney health initiative. (2013) (46)
New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity (2005) (46)
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. (2012) (46)
Cell populations and membrane attack complex in glomeruli of patients with post-streptococcal glomerulonephritis: identification using monoclonal antibodies by indirect immunofluorescence. (1984) (46)
ANCA-Associated Vasculitis - Refining Therapy with Plasma Exchange and Glucocorticoids. (2020) (46)
Predictors of 30-Day Hospital Readmission among Maintenance Hemodialysis Patients: A Hospital's Perspective. (2016) (46)
Production of fibronectin by epithelium in a skin equivalent. (1987) (45)
Membrane attack complex of complement in dermatitis herpetiformis. (1985) (45)
Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. (2018) (44)
Personal disaster preparedness of dialysis patients in North Carolina. (2011) (43)
Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. (1995) (43)
Controversies in small vessel vasculitis--comparing the rheumatology and nephrology views. (2007) (43)
Isolated prolactin deficiency: a case report. (1992) (42)
Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. (2016) (42)
Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis (2007) (42)
Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality. (2015) (40)
Do antineutrophil cytoplasmic autoantibodies cause Wegener's granulomatosis and other forms of necrotizing vasculitis? (1993) (40)
Monitoring Proteinase 3 Antineutrophil Cytoplasmic Antibodies for Detection of Relapses in Small Vessel Vasculitis (2003) (38)
Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers. (2006) (38)
Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. (2017) (38)
Length of stay and costs for hospitalized hemodialysis patients: nephrologists versus internists. (2000) (37)
High Basal Activity of the PTPN22 Gain-of-Function Variant Blunts Leukocyte Responsiveness Negatively Affecting IL-10 Production in ANCA Vasculitis (2012) (37)
The pathobiology of the terminal complement complexes. (1989) (36)
Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. (2016) (36)
B cell-mediated pathogenesis of ANCA-mediated vasculitis (2014) (36)
Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine. (1983) (34)
Immunoglobulin A-fibronectin aggregate levels in children and adults with immunoglobulin A nephropathy. (1993) (34)
Rituximab in ANCA-associated disease. (2010) (33)
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study (2018) (33)
In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases (2014) (33)
Community perspectives on kidney disease and health promotion from at-risk populations in rural North Carolina, USA. (2010) (33)
Treatment of lupus nephritis--a work in progress. (2000) (33)
Gene expression profiles of circulating leukocytes correlate with renal disease activity in IgA nephropathy. (2004) (32)
Health-related quality of life in glomerular disease. (2019) (32)
Wegener's granulomatosis, systemic vasculitis, and antineutrophil cytoplasmic autoantibodies. (1991) (32)
Serum Matrix Metalloproteinases MMP-2 and MMP-3 Levels in Dialysis Patients Vary Independently of CRP and IL-6 Levels (2002) (31)
Disposition of didanosine in HIV‐seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis (1996) (30)
Sickle cell nephropathy. (2020) (30)
False‐positive myeloperoxidase binding activity due to DNA/anti‐DNA antibody complexes: a source for analytical error in serologic evaluation of anti‐neutrophil cytoplasmic autoantibodies (2000) (30)
Frequency of anti‐bactericidal/permeability‐increasing protein (BPI) and anti‐azurocidin in patients with renal disease (1996) (29)
Antineutrophil cytoplasmic autoantibodies: disease associations, molecular biology, and pathophysiology. (1991) (29)
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases (2009) (29)
Single-item or two-item literacy screener to predict the S-TOFHLA among adult hemodialysis patients. (2014) (29)
Epidermolysis bullosa acquisita antigen, a major cutaneous basement membrane component, is synthesized by human dermal fibroblasts and other cutaneous tissues. (1986) (29)
Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. (2015) (29)
Immunosuppressive therapy of lupus nephritis (1998) (29)
Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli. (2004) (29)
Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis (2017) (28)
Pharmacokinetics of Mycophenolic Acid in Patients with Lupus Nephritis (2009) (28)
Myeloperoxidase specific anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA). (1990) (28)
Thoughts about the classification of small vessel vasculitis. (2004) (28)
Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. (2003) (27)
Immune complex induced glomerular lesions in C5 sufficient and deficient mice. (1986) (27)
Estrogen and progesterone regulation of carbonic anhydrase isoenzymes in guinea pig and rabbit uterus. (1971) (27)
Overcoming Barriers in Kidney Health-Forging a Platform for Innovation. (2016) (27)
Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (25)
Pathogenesis of ANCA-Associated Pulmonary Vasculitis (2018) (24)
Understanding the pathogenesis of ANCA: where are we today? (2002) (24)
Antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. (1993) (24)
Subtotal nephrectomy in the rabbit: a model of chronic hypercalcemia, nephrolithiasis, and obstructive nephropathy. (1986) (24)
Serum beta-human chorionic gonadotropin, estradiol and progesterone as early predictors of pathologic pregnancy. (1992) (23)
Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis. (2007) (23)
Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity (2019) (23)
Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis. (2015) (23)
Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. (2013) (23)
Effect of the antiprogestin RU486 on human ovarian steroidogenesis. (1987) (23)
Carbonic anhydrase isoenzymes in normal human endometrium and erythrocytes. (1972) (23)
Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (2016) (22)
Studies on complement deposits in epidermolysis bullosa acquisita and bullous pemphigoid. (1992) (22)
Diagnosis and management of glomerular diseases. (1997) (22)
Amelioration of immune complex-mediated glomerulonephritis by synthetic protease inhibitors. (1987) (22)
Reengineering Clinical Operations in a Medical Practice to Optimizethe Management of Anemia of Chronic Kidney Disease (2007) (22)
Genetically determined severity of anti-myeloperoxidase glomerulonephritis. (2013) (21)
Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure. (1990) (21)
Future molecular approaches to the diagnosis and treatment of glomerular disease. (2000) (20)
Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis (2015) (20)
Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N (2011) (20)
A radiotracer assay for carbonic anhydrase. (1971) (19)
Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. (2003) (19)
Glomerular Clinicopathologic Syndromes (2009) (19)
Human clinical trials in lupus nephritis. (2007) (19)
L1. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. (2013) (19)
Animal models in ANCA‐vasculitis (1995) (18)
Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis (2019) (17)
Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis (2010) (17)
Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases (2010) (16)
Pathogenesis of pulmonary vasculitis. (2004) (16)
Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. (2018) (16)
Difference in antigenic determinant profiles between human and rat myeloperoxidase (2003) (16)
Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. (2020) (16)
Nursing Intervention Aimed at Improving Self-Managementfor Persons with Chronic Kidney Disease in North Carolina Medicaid: A Pilot Project. (2015) (15)
The rise and fall of horror autotoxicus and forbidden clones. (2010) (15)
Alternative therapies and future intervention for treatment of membranous nephropathy. (2003) (15)
Clinical Features of Reported Ethylene Glycol Exposures in the United States (2015) (15)
Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. (2014) (15)
Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. (2015) (15)
Monoclonal antibodies to the apical chloride channel in Necturus gallbladder inhibit the chloride conductance. (1989) (15)
Goodpasture's syndrome revisited. A new perspective on glomerulonephritis and alveolar hemorrhage. (1990) (14)
Shared idiotypy among patients with myeloperoxidase-anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. (1996) (14)
ANCAs are also antimonocyte cytoplasmic autoantibodies. (2015) (14)
CHAPTER 24 – Renal and Systemic Vasculitis (2010) (14)
Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. (2006) (14)
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. (2011) (14)
Primum non nocere: Should adults with idiopathic FSGS receive steroids? (2003) (14)
Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. (1991) (14)
Influence of Clinical and Demographic Variables on Mycophenolic Acid Pharmacokinetics in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2009) (13)
Reconstitution of an epithelial chloride channel. Conservation of the channel from mudpuppy to man (1991) (13)
ANCA signaling: not just a matter of respiratory burst. (2001) (13)
Anti-neutrophil cytoplasmic autoantibodies: A review and highlights of the third international ANCA workshop (1991) (12)
Antigens of the human glomerulus. (1984) (12)
PTPN22 R620W Polymorphism and ANCA Disease Risk in White Populations: A Metaanalysis (2015) (12)
Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor. (1986) (12)
Anti-neutrophil cytoplasmic autoantibodies--a serologic marker for vasculitides. (1995) (12)
Do vasculitis categorization systems really matter? (2000) (11)
Bilateral simultaneous tubal pregnancies after ovulation induction with clomiphene-menotropin combination. (1977) (11)
Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis. (1992) (11)
The coming of age of serologic testing for anti-neutrophil cytoplasmic autoantibodies. (1994) (10)
ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation. (2020) (10)
Understanding Work: Moving Beyond the RVU. (2020) (10)
Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. (2014) (10)
A nephrological view of the classification of vasculitis. (1993) (9)
Maintenance of tolerance by regulation of anti-myeloperoxidase B cells. (2008) (9)
The spectrum of ANCA‐associated small vessel vasculitis and glomerulonephritis (1997) (9)
Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (2019) (9)
The Kidney Education Outreach Program's community-based screenings: participants' demographics and screening results. (2009) (9)
Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis. (2021) (8)
IL-17A in experimental glomerulonephritis: where does it come from? (2010) (8)
Nephropathology Consultation via Digitized Images a (1992) (8)
Pericarditis in renal failure. (1979) (8)
Palladin is Upregulated in Kidney Disease and Contributes to Epithelial Cell Migration After Injury (2015) (8)
The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy (2017) (8)
Pathogenesis of ANCA Vasculitis (2014) (7)
Restriction in Vκ Gene Use and Antigen Selection in Anti-Myeloperoxidase Response in Mice (2000) (7)
Declaracion internacional de consenso sobre el analisis y los informes de los anticuerpos contra el citoplasma de los neutrofilos (ANCA): International group for consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA) (2000) (7)
Expression of p300-truncated fragments results in the modulation of apoptosis in rat mesangial cells. (2000) (7)
Anca Vasculitis: Microscopic Polyangiitis, Wegener's Granulomatosis, and Churg-strauss Syndrome (2007) (7)
Autoimmunity: Does autoantigen complementarity underlie PR3-ANCA AAV? (2011) (7)
A renal biopsy in essential for the management of ANCA-positive patients with glomerulonephritis. (1996) (7)
ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value (2013) (7)
Mechanisms of vascular damage in ANCA vasculitis (2022) (7)
A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein (2007) (7)
Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy (2020) (7)
The clinical, serologic, and immunopathologic heterogeneity of cutaneous leukocytoclastic angiitis. (1993) (6)
Pathologic Classification of Vasculitis (2007) (6)
Nomenclature of Vasculitides: 2012 Revised International Chapel Hill Consensus Conference (2016) (6)
Immunologic Mechanisms of Vasculitis (2013) (6)
Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice. (2000) (6)
Complement channels in membranes: inhibition with a monoclonal antibody to a neoantigen of polymerized C9. (1984) (6)
Euestrogenic ovarian failure. (1977) (5)
Kinin B1 Receptor Is Important in the Pathogenesis of Myeloperoxidase-Specific ANCA GN. (2019) (5)
WS6_1 Anti-MPO antibodies cause granulomatosis in mice: an animal model of GPA (2017) (5)
Update on the pathobiology of vasculitis. (1995) (5)
Comparison of measures for prospective identification of venous stenoses. (1996) (5)
Exacerbation of adenomyosis symptomatology by estrogen-progestin therapy: a case report and histopathological observations. (1989) (5)
Vascular Diseases of the Kidney (2017) (5)
Tubo-ovarian transposition for multifocal obstructive tubal disease. (1980) (5)
Functionally effect regulatory B cells in patients with active ANCA vasculitis (2013) (4)
Neonatal foreskin substrate has limitations for the immunofluorescent screening of monoclonal antibodies. (1987) (4)
Acute renal failure secondary to leukocyte-mediated acute glomerular injury. (1992) (4)
Interleukin-18, neutrophils, and ANCA. (2006) (4)
Overview of the nomenclature and diagnostic categorization of vasculitis. (2000) (4)
Vasculitis: The elusive optimal induction strategy for vasculitis (2012) (4)
Glomerular Hematuria and the Utility of Urine Microscopy: A Review. (2022) (4)
A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis (2014) (4)
Understanding the role of rituximab in ANCA GN: regressing toward the mean. (2015) (4)
SY1_1 Classification of AAV Clinical Entity vs. Autoantibody Profile (2017) (4)
What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population (2014) (3)
Necrotizing Arteritis and Small Vessel Vasculitis (2006) (3)
The Third International Workshop on Antineutrophil Cytoplasmic Autoantibodies. Introduction. (1991) (3)
Autoantibodies: what's in their teeth? (2011) (3)
Antineutrophil cytoplasmic autoantibody in renal disease (1990) (3)
The effect of warfarin on prevalence of stroke in severe heart failure (1993) (3)
Wegener's granulomatosis mimicking a sternal abscess. (1996) (3)
Contraceptive Use and Elective Terminations in Women Enrolled in the Glomerular Disease Collaborative Network (2020) (2)
Epigenetics and complementary proteins (2011) (2)
Vascular permeability changes induced by antibodies to myeloperoxidase. (1993) (2)
Metabolic studies of sc5b 9 in the rat (1987) (2)
Association of Lupus Nephritis Histopathologic Classification With Venous Thromboembolism—Modification by Age at Biopsy (2021) (2)
L26. How antigens influence the disease: an immunologist point of view. (2013) (2)
The role of HL60 cells in the detection of antineutrophil cytoplasmic autoantibodies. (1991) (2)
Ig-class specificity of ANCA. (1990) (2)
Subfertility and early menopause in women with glomerular disease. (2021) (2)
ASN presidential address 2012: Time to cure kidney disease. (2013) (2)
Classification of ANCA vasculitides: The role of anti-neutrophil cytoplasmic autoantibody specificity for MPO or PR3 in disease recognition and prognosis (2012) (2)
Glomerulonephritis and Interstitial Nephritis (2011) (2)
Ethics and reproductive medicine. (1991) (2)
Vasculitis and anti-thyroid medication. (2008) (2)
Induction of Necrotizing and Crescentic Glomeru-Lonephritis (NCGN) and Small-Vessel Vasculitis (SVV) by Adoptive Transfer of Anti-Myeloperoxidase (Anti-MPO) Lymphocytes into Recombinase Activating Gene-2 Deficient (Rag-2 -/-) Mice (2002) (2)
Theodore E. Woodward Award. Do ANCA cause small vessel vasculitis? (2001) (1)
Microscopic polyangiitis: Pathogenesis (2016) (1)
New insights into mechanisms of immune-mediated glomerular diseases (2004) (1)
The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis. (2016) (1)
Treatment of Progressive Membranous Glomerulopathy (2020) (1)
Helping nephrologists become lifelong learners. (2008) (1)
PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease (2023) (1)
Induction of Pauci-Immune Necrotizing and Crescen-Tic Glomerulonephritis (NCGN) by Intravenous Administration of Anti-Myeloperoxidase (Anti-MPO) Antibodies to Recombinase Activating Gene-2 Deficient (Rag-2 -/-) Mice (2002) (1)
Novel Effects of Inflammatory Cell Proteases on Vascular Endothelia (2002) (1)
ANCA--diagnostic markers or pathogenic agents? (1992) (1)
ANCA disease patients have defective Treg function exacerbated by expansion of a suppression-resistant effector population (2013) (1)
T Cell Responsiveness to Complementary PR3 Protein Supports a Pathogenic Role of Autoantigen Complementarity in PR3-ANCA Autoimmune Disease (2007) (1)
Unexplained severe acute kidney injury with rapid recovery of kidney function 11 months later after the start of high-dose steroid therapy. (2014) (1)
Kidney Disease Progression in Membranous Nephropathy among Black Participants with High-Risk APOL1 Genotype (2023) (1)
Luteal phase hyperprolactinemia. (1994) (1)
What causes ANCA? (1997) (1)
NOMENCLATURE AND CLASSIFICATION OF VASCULITIS. AUTHORS' REPLY (1995) (1)
Hematometra associated with estrogen replacement therapy. (1993) (1)
The Kidney Care Prevention Program: an innovative approach to chronic kidney disease prevention. (2008) (1)
Anti-myeloperoxidase antibodies and clinical associations. (1990) (1)
Necrotizing Arteritis and Small-Vessel Vasculitis (2020) (0)
78: Variant Hemoglobin May Affect Erythropoietin Response in African-Americans Receiving Hemodialysis (2010) (0)
Anti-neutrophil cytoplasmic antibody (ANCA) target antigens, disease associations, and laboratory testing (1998) (0)
The nephrology quiz and questionnaire: 2006. (2007) (0)
Are ANCA pathogenetic? Pros and cons (1997) (0)
193. DEFICIENCY OF β2-INTEGRIN LFA-1 AMELIORATES MPO-ANCA INDUCED GLOMERULONEPHRITIS IN MICE (2019) (0)
B cell-mediated pathogenesis of ANCA-mediated vasculitis (2014) (0)
145. EFFECTS OF PSYCHOLOGICAL STRESS ON ANCA-ASSOCIATED VASCULITIS (AAV) DIAGNOSIS (2019) (0)
Book Review Cancer and the Kidney Edited by Eric P. Cohen. 276 pp., illustrated. New York, Oxford University Press, 2005. $125. 0-19-852644-X (2006) (0)
Kidney Disease: Goodpasture's Disease, Lupus Nephritis, ANCA-Associated Glomerulonephritis (2006) (0)
CARDIOVASCULAR OUTCOMES ARE WORSE IN MICROSCOPIC POLYANGIITIS COMPARED WITH GRANULOMATOSIS WITH POLYANGIITIS: DATA FROM AN INCEPTION COHORT OF PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED SYSTEMIC VASCULITIS (2015) (0)
PowerPoint Slides for: The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy (2017) (0)
Relevance of combined clinicopathologic phenotype and ANCA serotype in the diagnosis of ANCA vasculitis (2022) (0)
The Journal of Rheumatology Populations: A Metaanalysis R620W Polymorphism and ANCA Disease Risk in White PTPN22 (2014) (0)
CHAPTER 82 – Immunologic Mechanisms of Vasculitis (2008) (0)
Premature menopause: a report of two cases. (1974) (0)
Autoimmune hemolytic anemia and adenocarcinoma of the cecum: coexistence or coincidence? (1999) (0)
Contents Vol. 1, 2015 (2016) (0)
Injection of ANCA-No Neutrophils, No Glomerular Damage: The Role of Neutrophils in the Induction of Glomerulonephritis by Anti-Myeloperoxidase Antibodies. Am J Pathol 167: 39-45, 2005. (2005) (0)
The Pathogenesis and Consequences of Myeloperoxidase-Dependent ANCA Vasculitis and Glomerulonephritis (2021) (0)
Autoimmune Disease in the Kidney (2014) (0)
Contents Vol. 92, 2002 (2002) (0)
The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis (2022) (0)
CRRT in series with extracorporeal membrane oxygenation in pediatric patients (2010) (0)
Editorial / Publisher’s Note (2002) (0)
23 – Kidney Involvement in Systemic Vasculitis (2013) (0)
Supplementary Material for: Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis (2017) (0)
Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure (2013) (0)
Panel discussion on AIDS. (1989) (0)
Table of Contents (2020) (0)
191. CRITICAL MPO EPITOPES DRIVE THE CD4+ T CELL RESPONSE IN MPO-ANCA VASCULITIS (2019) (0)
Liver & Pancreas (2010) (0)
Gene-specific dna methylation changes predict relapse/remission in anca-associated vasculitis patients (2017) (0)
Expression of chemokines in murine crescentic glomerulonephritis (1999) (0)
for the Immunofluorescent Screening of Monoclonal Antibodies* (2010) (0)
B Cell Phenotypes of ANCA Patients Differ from Healthy Controls and Correlate with Disease Activity (2005) (0)
Low %CD5+ B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab (2013) (0)
Congenital tubal isolation: a case report. (1981) (0)
Introduction: Nomenclature and Classification (2019) (0)
Table of Contents. (2021) (0)
Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis (2013) (0)
ARIC MANUSCRIPT PROPOSAL FORM Manuscript #504 1. Title: Does a low ankle-brachial index predict the development of renal insufficiency? 2. Working group: (2001) (0)
Autoimmunity Key: Following Bolton’s Cues (2009) (0)
New etiopathogenic knowledge, or politics? Comment on the article by Falk et al Reply (2011) (0)
Pathogenesis and epidemiology of ANCA-associated vasculitides (2016) (0)
Methotrexate treatment of tubal pregnancy. (1994) (0)
192. ACTIVATION OF NEUTROPHILS WITH MPO-ANCA CORRELATES WITH MPO AUTOANTIGEN GENE EXPRESSION (2019) (0)
Abnormal glycosylation of serum IgG from patients with ANCA-associated systemic vasculitis: Relation to disease activity (2013) (0)
Case 24-2018: A 71-Year-Old Man with Acute Renal Failure and Hematuria. (2018) (0)
High calorie diet results in reversible obesity-related glomerulopathy in adult zebrafish regardless of dietary fat. (2022) (0)
Measuring Circulating Complement Activation Products in MPO and PR3 ANCA Vasculitis (2017) (0)
Should PLEX Be Used for Severe AKI and/or Pulmonary Hemorrhage in ANCA-Associated Vasculitis (AAV)? COMMENTARY. (2021) (0)
Relevance of Combined Clinicopathologic Phenotype and Antineutrophil Cytoplasmic Autoantibody Serotype in the Diagnosis of Antineutrophil Cytoplasmic Autoantibody Vasculitis (2022) (0)
Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis. (2022) (0)
List of Contributors (2020) (0)
Chapter 28 – Glomerulonephritis Caused by Anti-neutrophil Cytoplasmic Autoantibodies (2008) (0)
186. CHARACTERIZATION OF LOW-DENSITY GRANULOCYTES DURING ANCA VASCULITIS (2019) (0)
Systemic vasculitis and the kidney: ANCA Vasculitis and glomerulonephritis (2014) (0)
Plasma exchange led to a higher rate of renal recovery than intravenous methylpredisolone in severe vasculitis. (2008) (0)
Increases of PR3 and MPO Gene Transcription in Circulating Leukocyte of Anca-Associated Disease Correlate with Disease Activity (2002) (0)
Acknowledgement to the Reviewers (1998) (0)
Subject Index Vol. 92, 2002 (2002) (0)
The isolation of a mouse leukocytic pyrogen demonstrating its effect on the circadian temperature cycle of conditioned mice. (1966) (0)
P2_23 Induction of Cutaneous and Ear, Nose and Throat (ENT) Manifestations in a Mouse Model of MPO-ANCA Granulomatosis with Polyangiitis (2017) (0)
Erratum: Proteinase 3 sidesteps caspases and cleavesp21Waf1/Cip1/ Sdil to induce endothelial cell apoptosis (Kidney International (2004) 65 (75-84)) (2004) (0)
RENAL INJURY CAUSED BY DIFFERENT CATEGORIES OF VASCULITIS (2000) (0)
Nomenclature and pathologic features of vasculitides (2014) (0)
062. UPPER AND LOWER RESPIRATORY TRACT INVOLVEMENT IS SIMILAR IN MPO-ANCA AND PR3-ANCA GRANULOMATOSIS WITH POLYANGIITIS (2019) (0)
Antineutrophil cytoplasmic autoantibody-associated vasculitis on chronic dialysis. The Authors Reply (2010) (0)
Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronald J. Falk?

Ronald J. Falk is affiliated with the following schools:

University of North Carolina at Chapel Hill